我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

国产替罗非班治疗不稳定型心绞痛及非ST段抬高型心肌梗死患者的疗效(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2008年第3期
页码:
337-339，347
栏目:
临床研究
出版日期:
2008-05-20

文章信息/Info

Title:
Efficacy of Chinamade tirofiban in treatment of unstable angina and NonSTelavation myocardial infarction patients
作者:
杨飞燕1; 2; 杨波1; 陈曼华2
1.武汉大学人民医院心内科,湖北 武汉 430060； 2.武汉市中心医院心内科，湖北 武汉 430014
Author(s):
YANG Feiyan1; 2;  YANG Bo1;  CHEN Manhua2
1.Department of cardiology, Renmin Hospital, Wuhan University, Wuhan 430060, Hubei, China; 2.Department of cardiology, Wuhan Central Hospital, Wuhan 430014, Hubei, China
关键词:
替罗非班; 不稳定型心绞痛; 非ST段抬高型心肌梗死
Keywords:
tirofiban;  unstable angina;  nonSTelevation myocardial infarction
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 研究国产替罗非班对于不稳定型心绞痛（UA）及非ST段抬高型心肌梗死（NSTEMI）患者的疗效和安全性。方法 回顾性分析60例UA及NSTEMI患者的治疗，试验组30例应用替罗非班治疗（前半小时以01 μg/(kg·min)剂量静脉输入，再以减半剂量连续输入48 h），对照组30例未应用替罗非班，其余治疗两组一致。结果 试验组疗效在缓解心绞痛症状、心电图改善、减少硝酸甘油用量方面明显优于对照组，而且出血等不良反应发生率较低。结论 替罗非班对于UA及NSTEMI患者临床应用效果显著，安全性较好，值得临床推广。
Abstract:
AIM To study the efficacy and safety of Chinamade tirofiban in the treatment of unstable angina (UA) and NonSTelevation myocardial infarction (NSTEMI) patients. METHODS The therapy of 60 patients with UA or NSTEMI was retrospectively reviewed. The patients in tirofiban group (n=30) were given tirofiban \[load dose 04 μg/(kg·min)×30 min, maintaining dose 01 μg/(kg·min), iv drip, for 48 hours\] and the patients in control group (n=30) were given the same treatment except tirofiban. RESULTS The patients in tirofiban group had better results in alleviating angina, improving ST segment depression and reducing the dose of glonoine. Bleeding was few in the patients in tirofiban group. CONCLUSION Chinamade tirofiban is safe and effective in treating UA and NSTEMI patients.

参考文献/References

［1］ Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQwave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISMPLUS) Study Investigators ［J］. N Engl J Med, 1998, 338(21):1488-1497.

［2］ The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty ［J］. Circulation, 1997, 96(5):1445-1453.

［3］ A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators［J］. N Engl J Med, 1998, 338(21):1498-1505.

［4］ Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists［J］. Am J Cardiol, 2006, 97(3):426-429.

［5］ Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes(1)［J］. N Engl J Med, 1992, 326(4):242-250.

［6］ Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and nonSTsegment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina) ［J］. J Am Coll Cardiol, 2002, 40(7):1366-1374.

［7］ Sabatine MS, Morrow DA, Giugliano RP, et al. Implication of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/NonSTElevation Myocardial Infraction A Comparison of the Thrombolysis In Myocardial Infarction(TIMI) IIIB Trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy(TACTICS)TIMI18 rial［J］. Circulation, 2004, 109(7):874-80.

［8］ Giuqliano RP, Newby LK, Harrinqton RA, et al. The early glycoprotein IIb/IIIa inhibition in nonSTsegment elevation acute coronary syndrome(EARLY ACS)trial:a randomized placebocontrolled trial evaluating the clinical benefits of early frontloaded eptifibatide in the treatment of patients with nonSTsegment elevation acute coronary syndromestudy design and rationale［J］. Am Heart J, 2005, 149(6):994-1002.

［10］Goodman S. Enoxaparin and glycoprotein IIb/IIIa inhibition in nonSTelevation acute coronary syndrome: insights from the INTERACT trial［J］. Am Heart J, 2005, 149(4 Suppl):S73-S80.

［11］ Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE2 trial) ［J］. Am J Cardiol, 2005, 95(5):581-585.

［12］Lakovou I, Dangas G, Mintz GS, et al. Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or=75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions［J］. Am J Cardiol, 2004, 93(3):346-349.

［13］BrombergMarin G, MarinNeto JA, Parsons LS, et al. Effectiveness and Safety of Glycoprotein IIb/IIIa Inhibitors and Clopidogrel Alone and in Combination in NonSTSegment Elevation Myocardial Infarction(from the National Registry of Myocardial Infarction4)［J］. Am J Cardiol, 2006, 98(9):1125-1131.

［14］Rebeiz AG, Johanson P, Green CL, et al. Comparison of STsegment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials) ［J］. Am J Cardiol, 2005, 95(5):611-614.

备注/Memo

备注/Memo:
收稿日期：2007-04-30. 作者简介：杨飞燕，主治医师，硕士生 Email：feiyanyang@hotmail.com
更新日期/Last Update: